CD8A and neoplasm: Blocking PD-1 also promotes TCR signal activation, reactivates CD8+T cells depleted by antigenic stimulation, and reprograms the tumor microenvironment to promote inflammatory rather than inhibitory myeloid cell survival 42, 43.